公司简介
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology...
关联新闻
- First-Class Amenity Kits Have Become Holy Grail Collectibles
For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.
- Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.
- FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
A panel of outside experts advising the US FDA backed the safety of Grail's blood-based cancer detection test, Galleri, on Wednesday, but was divided on the evidence supporting its effectiveness.
- US FDA to hold advisory meeting to review Grail's multi-cancer test
Grail said on Friday the U.S. FDA plans to hold a meeting of outside experts to review its multi-cancer screening test Galleri in September, sending its shares up 4% in morning trade.